GLAMProject ID: 634928
Financé au titre de:
Laser Multiplexed Biosensor
Détails concernant le projet
Coût total:EUR 4 835 584,25
Contribution de l'UE:EUR 4 835 584
Sujet(s):PHC-10-2014 - Development of new diagnostic tools and technologies: in vitro devices, assays and platforms
Appel à propositions:H2020-PHC-2014-two-stageSee other projects for this call
Régime de financement:RIA - Research and Innovation action
Differential cancer diagnosis takes place daily in clinical settings for a better monitoring of patient responses to existing treatments. However outcome of this diagnosis is today still poor. Moreover, current technology to measure biomarker levels is expensive and sophisticated.
Most cancer biomarker analysis use blood or biological tissues as the main source of material. These biopsies must be analyzed in specialized laboratories incurring in some limitations: high cost; specialized personnel and equipment; large amounts of biological material; long outcome delivery time; time consuming processes.
Therefore it exist a real need and urgency to have new diagnostic devices that provide diagnosis, prognosis, and monitoring data faster and with exquisite ultra-sensitivity on time to take the appropriate decisions to improve personalized diagnosis and therapy.
The aim of GLAM project is to provide an innovative device to fulfill these requirements using soluble biomarkers for personalized diagnosis and therapy monitoring.
Specifically we will design and develop a new diagnostic tool to detect biomarkers from biofluids obtained in a non-invasive manner, specifically focusing to urine and to genitourinary cancers, to help oncologist to take better treatment decisions, approaching personalized medicine.
GLAM will develop an integrated device based on novel label-free photonic biosensors with ultra-sensitivity, simplicity of use, portability, multiplexing and low cost. GLAM capitalizes on the unprecedented sensitivity achieved using laser microring resonators to detect key biomarkers in tumor development and treatment. Point of Care of the device will be carried out by preclinical and clinical sample analysis of genitourinary cancer patients to warrant personalized medicine.
Importantly the GLAM unique technology will make the device also usable with other biofluids and might also be used to help physicians with other biomarker driven.
Contribution de l'UE: EUR 692 632,50
CARRER DE LA INNOVACIO 2
Contribution de l'UE: EUR 491 125,50
CARRER BALDIRI REIXAC PLANTA 2A 10-12
Contribution de l'UE: EUR 817 885
7522 NB ENSCHEDE
Contribution de l'UE: EUR 323 625
Beit Hillel 3
67017 TEL AVIV-JAFFO
Contribution de l'UE: EUR 374 412,50
Avenue Franklin Roosevelt 50
Contribution de l'UE: EUR 574 275
AVINGUDA CARL FRIEDRICH GAUSS 3
Contribution de l'UE: EUR 283 316
GEERT GROOTEPLEIN NOORD 9
6525 EZ NIJMEGEN
Contribution de l'UE: EUR 467 700
OMLADINSKIH BRIGADA 86 P
Contribution de l'UE: EUR 400 812,50
Bain Square 5
EH54 7DQ Livingston
Contribution de l'UE: EUR 409 800
BOULEVARD GENERAL WAHIS 53